{"title":"ASCO的亮点","authors":"F. Griesinger","doi":"10.19080/ijoprs.2019.04.555634","DOIUrl":null,"url":null,"abstract":"The Immune-Checkpoint Inhibitor (ICI) therapy that has evolved as a standard of care for stage IV and III is now moving into the early stages. Three studies on ICI-induction therapy in early or locally advanced NSCLC (stages II and III) were presented at ASCO.","PeriodicalId":257243,"journal":{"name":"International Journal of Pulmonary & Respiratory Sciences","volume":"142 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Highlights of ASCO\",\"authors\":\"F. Griesinger\",\"doi\":\"10.19080/ijoprs.2019.04.555634\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The Immune-Checkpoint Inhibitor (ICI) therapy that has evolved as a standard of care for stage IV and III is now moving into the early stages. Three studies on ICI-induction therapy in early or locally advanced NSCLC (stages II and III) were presented at ASCO.\",\"PeriodicalId\":257243,\"journal\":{\"name\":\"International Journal of Pulmonary & Respiratory Sciences\",\"volume\":\"142 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pulmonary & Respiratory Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.19080/ijoprs.2019.04.555634\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pulmonary & Respiratory Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19080/ijoprs.2019.04.555634","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Immune-Checkpoint Inhibitor (ICI) therapy that has evolved as a standard of care for stage IV and III is now moving into the early stages. Three studies on ICI-induction therapy in early or locally advanced NSCLC (stages II and III) were presented at ASCO.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
